Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
Trump orders resumption of nuclear tests, raising concerns about international agreements and lost expertise.
Novo Nordisk challenges Pfizer's acquisition of Metsera with a $6.5 billion bid, sparking a high-stakes contest for obesity and GLP-1 assets.
Novo Nordisk makes a bold $9 billion bid to acquire Metsera, challenging Pfizer's earlier $4.9 billion deal and intensifying the race for dominance in the lucrative obesity drug market.
Trump orders resumption of nuclear tests, raising concerns about international agreements and lost expertise.
Novo Nordisk challenges Pfizer's acquisition of Metsera with a $6.5 billion bid, sparking a high-stakes contest for obesity and GLP-1 assets.